{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:09:57Z","timestamp":1785607797802,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00115-019-00852-5","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T10:02:50Z","timestamp":1578909770000},"page":"216-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["S3-Leitlinie Bipolare St\u00f6rungen \u2013 1.\u00a0Update 2019","German S3 guidelines on bipolar disorders\u2014first update 2019"],"prefix":"10.1007","volume":"91","author":[{"given":"T.","family":"Bschor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Grunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Lewitzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Scherk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Severus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"852_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40345-017-0089-1","volume":"5","author":"A Bocchetta","year":"2017","unstructured":"Bocchetta\u00a0A, Cabras\u00a0F, Pinna\u00a0M et al (2017) An observational study of 110 elderly lithium-treated patients followed up for 6 years with particular reference to renal function. Int J Bipolar Disord 5:19","journal-title":"Int J Bipolar Disord"},{"key":"852_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/archpsyc.57.5.481","volume":"57","author":"CL Bowden","year":"2000","unstructured":"Bowden\u00a0CL, Calabrese\u00a0JR, Mcelroy\u00a0SL et al (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57:481\u2013489","journal-title":"Arch Gen Psychiatry"},{"key":"852_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00115-013-3766-z","volume":"84","author":"T Bschor","year":"2013","unstructured":"Bschor\u00a0T, Bauer\u00a0M (2013) Nebenwirkungs- und Risikoprofil von Lithium. Kritische Bewertung einer systematischen \u00dcbersicht und Metaanalyse. Nervenarzt 84:860\u2013863","journal-title":"Nervenarzt"},{"key":"852_CR4","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00115-014-4083-x","volume":"85","author":"T Bschor","year":"2014","unstructured":"Bschor\u00a0T, M\u00fcller-Oerlinghausen\u00a0B, Stoppe\u00a0G et al (2014) Neue Fakten zur Phasenprophylaxe der bipolar affektiven Erkrankung. Nervenarzt 85:1166\u20131170","journal-title":"Nervenarzt"},{"key":"852_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese\u00a0JR, Keck\u00a0PE Jr., Macfadden\u00a0W et al (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351\u20131360","journal-title":"Am J Psychiatry"},{"key":"852_CR6","doi-asserted-by":"publisher","first-page":"f3646","DOI":"10.1136\/bmj.f3646","volume":"346","author":"A Cipriani","year":"2013","unstructured":"Cipriani\u00a0A, Hawton\u00a0K, Stockton\u00a0S et al (2013) Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346:f3646","journal-title":"BMJ"},{"key":"852_CR7","volume-title":"S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen. Langversion 2.0, Update Mai 2019","author":"DGBS","year":"2019","unstructured":"DGBS, DGPPN (2019) S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen. Langversion 2.0, Update Mai 2019 (www.leitlinie-bipolar.de)"},{"key":"852_CR8","volume-title":"S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen. Langversion 1.0, Mai 2012","author":"DGBS","year":"2012","unstructured":"DGBS, DGPPN (2012) S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen. Langversion 1.0, Mai 2012 (www.leitlinie-bipolar.de)"},{"key":"852_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00115-013-3919-0","volume":"85","author":"S K\u00f6hler","year":"2014","unstructured":"K\u00f6hler\u00a0S, Bauer\u00a0M, Bschor\u00a0T (2014) Pharmakologische Behandlung der bipolaren Depression: Evidenz aus klinischen Leitlinien und Behandlungsempfehlungen. Nervenarzt 85:1075\u20131083","journal-title":"Nervenarzt"},{"key":"852_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-0033-1364004","volume":"47","author":"S K\u00f6hler","year":"2014","unstructured":"K\u00f6hler\u00a0S, Gaus\u00a0S, Bschor\u00a0T (2014) The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry 47:53\u201359","journal-title":"Pharmacopsychiatry"},{"key":"852_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1399-5618.2007.00467.x","volume":"9","author":"RW Kupka","year":"2007","unstructured":"Kupka\u00a0RW, Altshuler\u00a0LL, Nolen\u00a0WA et\u00a0al (2007) Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9:531\u2013535","journal-title":"Bipolar Disord"},{"key":"852_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00213-016-4215-z","volume":"233","author":"H Li","year":"2016","unstructured":"Li\u00a0H, Gu\u00a0N, Zhang\u00a0H et al (2016) Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a\u00a0multi-center, randomized, double-blind, placebo-controlled trial. Psychopharmacology 233:1289\u20131297","journal-title":"Psychopharmacology"},{"key":"852_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1755-5949.2011.00260.x","volume":"18","author":"RW Licht","year":"2012","unstructured":"Licht\u00a0RW (2012) Lithium: still a\u00a0major option in the management of bipolar disorder. CNS Neurosci Ther 18:219\u2013226","journal-title":"CNS Neurosci Ther"},{"key":"852_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel\u00a0A, Cucchiaro\u00a0J, Silva\u00a0R et al (2014) Lurasidone monotherapy in the treatment of bipolar I depression: a\u00a0randomized, double-blind, placebo-controlled study. Am J Psychiatry 171:160\u2013168","journal-title":"Am J Psychiatry"},{"key":"852_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel\u00a0A, Cucchiaro\u00a0J, Silva\u00a0R et al (2014) Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a\u00a0randomized, double-blind, placebo-controlled study. Am J Psychiatry 171:169\u2013177","journal-title":"Am J Psychiatry"},{"key":"852_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4088\/JCP.08m04942gre","volume":"71","author":"SL Mcelroy","year":"2010","unstructured":"Mcelroy\u00a0SL, Weisler\u00a0RH, Chang\u00a0W et al (2010) A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J\u00a0Clin Psychiatry 71:163\u2013174","journal-title":"J Clin Psychiatry"},{"key":"852_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bdi.12027","volume":"15","author":"WA Nolen","year":"2013","unstructured":"Nolen\u00a0WA, Weisler\u00a0RH (2013) The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a\u00a0post hoc analysis of a\u00a0double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord 15:100\u2013109","journal-title":"Bipolar Disord"},{"key":"852_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1055\/s-0043-112884","volume":"11","author":"B Ochs","year":"2017","unstructured":"Ochs\u00a0B, Bschor\u00a0T (2017) SOP Lithiumaugmentation. Psych Up2date 11:293\u2013297","journal-title":"Psych Up2date"},{"key":"852_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/a-0627-7489","volume":"51","author":"E Severus","year":"2018","unstructured":"Severus\u00a0E, Bauer\u00a0M, Geddes\u00a0J (2018) Efficacy and effectiveness of lithium in the long-term treatment of bipolar disorders: an update 2018. Pharmacopsychiatry 51:173\u2013176","journal-title":"Pharmacopsychiatry"},{"key":"852_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","volume":"121","author":"T Suppes","year":"2010","unstructured":"Suppes\u00a0T, Datto\u00a0C, Minkwitz\u00a0M et\u00a0al (2010) Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J\u00a0Affect Disord 121:106\u2013115","journal-title":"J Affect Disord"},{"key":"852_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"ME Thase","year":"2006","unstructured":"Thase\u00a0ME, Macfadden\u00a0W, Weisler\u00a0RH et al (2006) Efficacy of quetiapine monotherapy in bipolar I and II depression: a\u00a0double-blind, placebo-controlled study (the BOLDER II study). J\u00a0Clin Psychopharmacol 26:600\u2013609","journal-title":"J Clin Psychopharmacol"},{"key":"852_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40345-017-0096-2","volume":"5","author":"L Tondo","year":"2017","unstructured":"Tondo\u00a0L, Abramowicz\u00a0M, Alda\u00a0M et al (2017) Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. Int J Bipolar Disord 5:27","journal-title":"Int J Bipolar Disord"},{"key":"852_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40345-019-0151-2","volume":"7","author":"L Tondo","year":"2019","unstructured":"Tondo\u00a0L, Alda\u00a0M, Bauer\u00a0M et\u00a0al (2019) Clinical use of lithium salts: guide for users and prescribers. Int J Bipolar Disord 7:16","journal-title":"Int J Bipolar Disord"},{"key":"852_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1192\/bjp.bp.114.147587","volume":"208","author":"LN Yatham","year":"2016","unstructured":"Yatham\u00a0LN, Vieta\u00a0E, Goodwin\u00a0GM et al (2016) Agomelatine or placebo as adjunctive therapy to a\u00a0mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 208:78\u201386","journal-title":"Br J Psychiatry"},{"key":"852_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","volume":"71","author":"AH Young","year":"2010","unstructured":"Young\u00a0AH, Mcelroy\u00a0SL, Bauer\u00a0M et al (2010) A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J\u00a0Clin Psychiatry 71:150\u2013162","journal-title":"J Clin Psychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-00852-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T21:34:12Z","timestamp":1610487252000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-00852-5"}},"subtitle":["Was ist neu in der Pharmakotherapie?","What is new in pharmacotherapy?"],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-00852-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"13 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Grunze erhielt in den letzten drei Jahren Vortrags- und Beraterhonorare von Janssen-Cilag, Recordati und Sage Therapeutics. U.\u00a0Lewitzka hat einmalig eine Kongressreiseunterst\u00fctzung von Janssen-Cilag angenommen. H.\u00a0Scherk erhielt in den letzten drei Jahren Vortrags- und Beraterhonorare von Janssen-Cilag und Shire. E.\u00a0Severus hat als Vortragender bei wissenschaftlichen Fortbildungsveranstaltungen f\u00fcr Servier, Roche und Aristo ein Honorar erhalten. M.\u00a0Bauer war beratend t\u00e4tig f\u00fcr Janssen-Cilag, neuraxpharm und Sunovion und hat Vortragshonorare von Hexal AG, Janssen-Cilag und Sunovion angenommen. T.\u00a0Bschor und C.\u00a0Baethge haben keine finanziellen Interessenkonflikte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}